Hyphens Pharma International - Phillip Securities 2025-03-10: Investing For Future Growth

• Hyphens Pharma is a branded consumer healthcare company (nutraceuticals, medical aesthetics and pharmaceuticals) with a regional presence.
• FY24 earnings were below expectations. Hyphens Pharma's revenue and PATMI were 102%/94% of our FY24e forecast. 2H24 PATMI declined 4% y-o-y to S$4.8mil due to weaker margins in proprietary brands, a decline in Vietnam sales and higher losses from DocMed.
• - Read this at SGinvestors.io -

The Positive

Growth in specialty pharma.

• - Read this at SGinvestors.io -
• Vietnam suffered from overstocking by distributors. We believe most of the growth in 2H24 was from medical aesthetics in Malaysia.

The Negative

DocMed is still at the investment stage.

• Read more at SGinvestors.io.

Above is an excerpt from a report by Phillip Securities Research.
Clients of Phillip Capital may be the first to access the full PDF report @ https://www.stocksbnb.com/.

Previous report by Phillip:
2024-08-21 Hyphens Pharma International - New Products & Wider Distribution.

Price targets by 2 other brokers at Hyphens Pharma Target Prices.

Listing of research reports at Hyphens Pharma Analyst Reports.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividend Payout Dates & Corporate Actions,
Hyphens Pharma News